RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB5 days ago · Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for ...
In sustained rare disease push, Recordati lays out $825M upfront …
WEB5 days ago · Enjaymo reeled in sales of around 100 million euros ($110 million) over 12 months ending in August, Recordati said in its release. The drug is expected to generate revenues in the vicinity of 150 ...
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for …
WEB6 days ago · Recordati is paying $825 million up front for global rights to Enjaymo, a drug that is approved in the U.S., Japan, and Europe. If the drug achieves sales milestones, the company could pay out up ...
Sanofi Offloads Rare Autoimmune Drug to Recordati in
WEB5 days ago · Sanofi sold Enjaymo, its humanized monoclonal antibody treatment for the rare autoimmune disorder cold agglutinin disease, to Italy’s Recordati in an agreement potentially worth more than $1 billion.. Under the terms of the deal, Milan-based Recordati will pay $825 million upfront and will pledge up to $250 million in sales-based milestones.
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEBOct 3, 2024 · Recordati (REC.MI) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care and ...
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
WEB5 days ago · Oct 4, 2024 6:47am. By Andrea Figueras. Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 ...
Recordati shares rise as investors reportedly circle CVC stake
WEBJun 18, 2024 · Shares in Italian drugmaker Recordati rose almost 3% on Tuesday, boosted by a report that investment funds KKR and TPG had expressed preliminary interest in buying a stake in the company.
Italy's Recordati hikes 2024 guidance after core profit rises 11.5%
WEBJul 30, 2024 · Italian drug maker Recordati raised its guidance for 2024 on Tuesday buoyed by positive momentum in its mainline Specialty and Primary Care and Rare Disease segments and an 11.5% rise in...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE …
WEB5 days ago · Milan, 4 th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults ...
CVC Explores Options for €11 Billion Drugmaker Recordati - Bloomberg.com
WEBApr 23, 2024 · CVC Capital Partners is exploring options for its controlling stake in Italian drugmaker Recordati SpA, according to people familiar with the matter.